BioNano Genomics Inc vs VanEck Australian Floating Rate ETF — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.20M), while VanEck Australian Floating Rate ETF trades at $50.97. The key difference: VanEck Australian Floating Rate ETF is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | FLOT | |
|---|---|---|
Market Cap | $13.20M | — |
Sector | Health | Sector/Thematic |
52-Week High | $4.92 | $51.09 |
52-Week Low | $1.09 | $50.72 |
Enterprise Value | $15.81M | — |
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
FLOT trades at $50.98 with no recent price change. Technical indicators show a bullish moving average signal but bearish oscillators, with the 6-day RSI at 88.89 indicating overbought conditions. Recent dividends of $0.17 and $0.18 per share reflect income distribution. The ETF focuses on high-quality floating rate bonds, offering a 4.0% SEC yield, with potential upside if the Federal Reserve raises rates.
The outlook for FLOT is tied to interest rate movements, with potential gains from rising yields but risks from inflation and geopolitical tensions. Investors seeking short-term income may find value, though overbought technicals suggest caution. Credit quality remains high, but macroeconomic shifts could impact performance.
Trailing returns across standard periods
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →